Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytomegalovirus Infections | 3 | 2020 | 85 | 1.870 |
Why?
|
| Cytomegalovirus | 3 | 2020 | 83 | 1.440 |
Why?
|
| HIV Infections | 5 | 2022 | 1000 | 1.300 |
Why?
|
| Liver Cirrhosis | 2 | 2015 | 61 | 0.990 |
Why?
|
| Hepatitis C | 2 | 2015 | 70 | 0.950 |
Why?
|
| Organ Transplantation | 2 | 2020 | 43 | 0.870 |
Why?
|
| Antiviral Agents | 3 | 2020 | 133 | 0.830 |
Why?
|
| BK Virus | 2 | 2022 | 13 | 0.770 |
Why?
|
| Polyomavirus Infections | 2 | 2022 | 27 | 0.760 |
Why?
|
| Transplant Recipients | 2 | 2022 | 26 | 0.750 |
Why?
|
| Kidney Transplantation | 2 | 2022 | 153 | 0.650 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 17 | 0.570 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 55 | 0.560 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2015 | 227 | 0.550 |
Why?
|
| Antigens, CD | 1 | 2015 | 104 | 0.550 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 94 | 0.550 |
Why?
|
| Thromboplastin | 1 | 2015 | 7 | 0.540 |
Why?
|
| Tumor Virus Infections | 1 | 2015 | 18 | 0.540 |
Why?
|
| Tissue and Organ Procurement | 1 | 2015 | 37 | 0.530 |
Why?
|
| Immunosuppressive Agents | 2 | 2015 | 166 | 0.530 |
Why?
|
| Hepatitis C, Chronic | 1 | 2015 | 81 | 0.490 |
Why?
|
| Interleukin-10 | 1 | 2013 | 43 | 0.480 |
Why?
|
| Stomatitis, Aphthous | 1 | 2012 | 3 | 0.460 |
Why?
|
| Thalidomide | 1 | 2012 | 7 | 0.460 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 216 | 0.450 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 179 | 0.440 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 98 | 0.430 |
Why?
|
| Venous Thrombosis | 1 | 2012 | 55 | 0.430 |
Why?
|
| Asymptomatic Infections | 1 | 2011 | 3 | 0.420 |
Why?
|
| Syphilis | 1 | 2011 | 6 | 0.420 |
Why?
|
| Gonorrhea | 1 | 2011 | 8 | 0.420 |
Why?
|
| Chlamydia Infections | 1 | 2011 | 8 | 0.420 |
Why?
|
| Isoniazid | 1 | 2011 | 7 | 0.420 |
Why?
|
| Antitubercular Agents | 1 | 2011 | 17 | 0.420 |
Why?
|
| Tuberculosis | 1 | 2011 | 26 | 0.410 |
Why?
|
| Viral Load | 3 | 2020 | 206 | 0.400 |
Why?
|
| Renal Dialysis | 1 | 2011 | 132 | 0.380 |
Why?
|
| Coinfection | 3 | 2015 | 33 | 0.350 |
Why?
|
| Drug Resistance, Viral | 2 | 2019 | 39 | 0.350 |
Why?
|
| Humans | 15 | 2022 | 32988 | 0.300 |
Why?
|
| HIV-1 | 2 | 2022 | 447 | 0.270 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2015 | 156 | 0.240 |
Why?
|
| Middle Aged | 6 | 2015 | 11219 | 0.230 |
Why?
|
| Mass Screening | 2 | 2015 | 203 | 0.210 |
Why?
|
| Kidney Diseases | 1 | 2022 | 152 | 0.200 |
Why?
|
| Cross-Sectional Studies | 2 | 2015 | 1058 | 0.200 |
Why?
|
| Male | 7 | 2015 | 17726 | 0.190 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 24 | 0.190 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 54 | 0.190 |
Why?
|
| Viral Structural Proteins | 1 | 2019 | 5 | 0.180 |
Why?
|
| Viral Proteins | 1 | 2019 | 28 | 0.180 |
Why?
|
| Stem Cell Transplantation | 2 | 2019 | 52 | 0.180 |
Why?
|
| Genomics | 1 | 2019 | 51 | 0.180 |
Why?
|
| Drugs, Investigational | 1 | 2018 | 10 | 0.180 |
Why?
|
| Forecasting | 1 | 2018 | 136 | 0.170 |
Why?
|
| Research Design | 1 | 2020 | 244 | 0.160 |
Why?
|
| Adult | 5 | 2015 | 9848 | 0.160 |
Why?
|
| Female | 5 | 2015 | 18423 | 0.150 |
Why?
|
| Strongyloidiasis | 1 | 2015 | 1 | 0.140 |
Why?
|
| Strongyloides stercoralis | 1 | 2015 | 1 | 0.140 |
Why?
|
| Nephrology | 1 | 2015 | 16 | 0.130 |
Why?
|
| Confusion | 1 | 2015 | 15 | 0.130 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 149 | 0.130 |
Why?
|
| Exanthema | 1 | 2015 | 14 | 0.130 |
Why?
|
| Influenza, Human | 1 | 2015 | 53 | 0.130 |
Why?
|
| Flow Cytometry | 1 | 2015 | 216 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2015 | 95 | 0.130 |
Why?
|
| Biopsy | 1 | 2015 | 277 | 0.130 |
Why?
|
| Internet | 1 | 2015 | 112 | 0.120 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 10 | 0.120 |
Why?
|
| HLA-DR Antigens | 1 | 2013 | 27 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2015 | 215 | 0.120 |
Why?
|
| Surgeons | 1 | 2015 | 98 | 0.120 |
Why?
|
| Liver | 1 | 2015 | 213 | 0.120 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 144 | 0.120 |
Why?
|
| Physicians | 1 | 2015 | 136 | 0.120 |
Why?
|
| Sepsis | 1 | 2015 | 160 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2012 | 36 | 0.110 |
Why?
|
| United States | 2 | 2020 | 2632 | 0.110 |
Why?
|
| Reagins | 1 | 2011 | 1 | 0.110 |
Why?
|
| Baltimore | 1 | 2011 | 16 | 0.110 |
Why?
|
| Life Style | 1 | 2013 | 226 | 0.110 |
Why?
|
| Tuberculin Test | 1 | 2011 | 14 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2011 | 40 | 0.100 |
Why?
|
| Anti-HIV Agents | 1 | 2012 | 171 | 0.100 |
Why?
|
| Chicago | 1 | 2013 | 957 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2020 | 4036 | 0.090 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 368 | 0.090 |
Why?
|
| Hospitalization | 1 | 2011 | 367 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2015 | 1117 | 0.080 |
Why?
|
| Aged | 2 | 2015 | 10542 | 0.060 |
Why?
|
| Anti-Retroviral Agents | 1 | 2022 | 51 | 0.060 |
Why?
|
| Public Health | 1 | 2022 | 69 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 121 | 0.050 |
Why?
|
| Toxicology | 1 | 2020 | 1 | 0.050 |
Why?
|
| Government Regulation | 1 | 2020 | 8 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 74 | 0.050 |
Why?
|
| Endodeoxyribonucleases | 1 | 2019 | 1 | 0.050 |
Why?
|
| Acetates | 1 | 2019 | 26 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2019 | 39 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 42 | 0.040 |
Why?
|
| Quinazolines | 1 | 2019 | 28 | 0.040 |
Why?
|
| Animals | 2 | 2020 | 5371 | 0.040 |
Why?
|
| Orthomyxoviridae | 1 | 2015 | 4 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 5 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 26 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2015 | 103 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 178 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 57 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2015 | 20 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 462 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 626 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2015 | 3835 | 0.020 |
Why?
|